

Exploration of the effects of fospropofol disodium in anesthesia induction for elderly hip surgery

Submission date 18/06/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 24/06/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 25/03/2026	Condition category Surgery	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study looked at two medications, fospropofol disodium and etomidate. To determine whether fospropofol disodium can be effectively and safely used for anesthetic induction in elderly patients undergoing hip surgery. To assess whether fospropofol disodium provides superior hemodynamic stability compared to etomidate during anesthetic induction in elderly hip surgery patients. To compare the incidence of adverse events between fospropofol disodium and etomidate, specifically evaluating injection pain, myoclonus, and adrenal suppression.

Who can participate?

Elderly patients (65-74 years), BMI 18-27 kg/m², ASA physical status I-III, scheduled for hip surgery under general anesthesia requiring endotracheal intubation.

What does the study involve?

Participants were randomly placed into two groups. One group received fospropofol disodium, the other received etomidate

What are the possible benefits and risks of participating?

To optimize anesthetic induction and intraoperative management by maintaining hemodynamic stability, minimizing adverse events, simplifying medication regimens (including reduced maintenance doses), shortening recovery time, and accelerating postoperative rehabilitation. As a water-soluble formulation, fospropofol disodium effectively mitigates injection pain, myoclonus, nausea/vomiting, and other adverse reactions, providing superior induction experience for patients.

Where is the study run from?

The First People's Hospital of Changzhou (China)

When is the study starting and how long is it expected to run for?

June 2025 to December 2025

Who is funding the study?
The First People's Hospital of Changzhou (China)

Who is the main contact?
qiulanmz@163.com

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Lan Qiu

Contact details

The First People's Hospital of Changzhou
Changzhou
China
213000
+86 519-68870312
qiulanmz@163.com

Additional identifiers

Study information

Scientific Title

Randomized controlled trial of fospropofol disodium versus etomidate for anesthetic induction in elderly patients undergoing hip surgery: a randomized controlled trial

Acronym

FDE-HF

Study objectives

Fospropofol disodium demonstrates safe and effective application for anesthetic induction in elderly patients undergoing hip surgery. Compared with the commonly used clinical induction agent etomidate, it provides greater hemodynamic stability, more effectively suppresses intubation-induced stress responses, and exhibits a lower incidence of complications such as myoclonus and injection pain.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 07/05/2025, Ethics Committee of First People's Hospital of Changzhou (The First People's Hospital of Changzhou, Changzhou, 213000, China; +86 519-68870965; czyygcp@czfph.com), ref: 2025 CL059

Study design

Single-centre single-blinded prospective randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Elderly hip surgery patients

Interventions

Patients were randomly allocated into two groups (1:1 ratio) using a computer-generated randomisation list created by an independent biostatistician before patient enrolment. Block randomisation was not used. Allocation was concealed, and both patients and outcome assessors were blinded to group assignments.

Patients were randomly assigned to receive either intraoperative Fospropofol disodium infusion (10 mg/kg) or Etomidate infusion (0.3 mg/kg)

The treatment duration is defined as the time from anesthesia induction until discharge from the post anesthesia care unit (PACU), and the follow-up period is 48 hours postoperatively

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Fospropofol disodium, etomidate

Primary outcome(s)

Time to loss of consciousness, measured by recording the interval from drug injection until both disappearance of the eyelash reflex and failure to respond to verbal command on two consecutive attempts

Key secondary outcome(s)

1. Hemodynamic parameters including heart rate, systolic, diastolic, and mean arterial pressure are measured using noninvasive monitoring at before induction of anesthesia, loss of consciousness, immediately after tracheal intubation, surgical incision, 20 minutes after surgical incision
2. Side effects including postoperative nausea and vomiting are documented based on clinical observation and medication use within the first 24 hours
3. Recovery Time is recorded based on the time to extubation time after surgery
4. postoperative delirium is measured using a Confusion Assessment Method scale at 48 hours postoperatively
5. Success rate of anesthesia induction is measured using counting successful inductions as a proportion of the total number of participants in each group
6. Incidence of injection pain and myoclonus within 30 seconds of initial dose administration are documented based on clinical observation

7. Total dosage of sufentanil, remifentanil, propofol, and vasoactive drugs used is measured using data obtained from the intravenous device

Completion date

31/12/2025

Eligibility

Key inclusion criteria

1. Elderly patients (65-74 years)
2. BMI 18-27 kg/m²
3. ASA physical status I-III
4. Scheduled for hip surgery under general anesthesia requiring endotracheal intubation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Lower age limit

65 years

Upper age limit

74 years

Sex

All

Total final enrolment

120

Key exclusion criteria

1. Refusal of general anesthesia
2. Allergy to general anesthetics
3. Preoperative cognitive impairment or significant hepatic/renal dysfunction
4. Baseline blood pressure $\geq 180/110$ mmHg or $\leq 90/60$ mmHg
5. Symptomatic cardiovascular, cerebrovascular, or respiratory diseases
6. Scheduled for bilateral joint surgery
7. Revision arthroplasty
8. Polytrauma
9. History of systemic or regional anesthesia within 3 months

Date of first enrolment

21/07/2025

Date of final enrolment

15/11/2025

Locations

Countries of recruitment

China

Study participating centre

The First People's Hospital of Changzhou

Changzhou

China

213000

Sponsor information

Organisation

The First People's Hospital of Changzhou

ROR

<https://ror.org/01gaj0s81>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

The First People's Hospital of Changzhou

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from (Lan Qiu ,email address qiulanmz@163.com)

IPD sharing plan summary

Available on request